Bausch Health Companies BHC Diversified — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's diversified — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's diversified — R&D?
- Bausch Health Companies (BHC) reported diversified — R&D of $3M in Q1 2026.
- How has Bausch Health Companies's diversified — R&D changed year-over-year?
- Bausch Health Companies's diversified — R&D decreased by 0.0% year-over-year, from $3M to $3M.
- What is the long-term trend for Bausch Health Companies's diversified — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's diversified — R&D has grown at a -17.6% compound annual growth rate (CAGR), from $25M to $14M.
- What does diversified — R&D mean?
- Captures the costs incurred for research and development activities specifically dedicated to the Diversified segment's product pipeline. This investment is critical for long-term innovation and maintaining the competitive edge of the segment's product portfolio. It reflects the company's commitment to future growth through scientific advancement.